BioCardia (BCDA) Current Deferred Revenue (2015 - 2023)

BioCardia (BCDA) has reported Current Deferred Revenue for 9 consecutive years, with $333000.0 the latest figure, recorded in Q2 2023.

• On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $333000.0 in Q2 2023; TTM through Jun 2023 was $333000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $341000.0, down 59.74% from the prior year.
• Current Deferred Revenue was $333000.0 for Q2 2023 at BioCardia, down from $340000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $1.4 million in Q2 2021 and troughed at $90000.0 in Q3 2020.
• A 5-year average of $483941.2 and a median of $340000.0 in 2023 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue sank 64.29% in 2020 and surged 1262.5% in 2021, its largest moves.
• Over 5 years, Current Deferred Revenue stood at $102000.0 in 2019, then jumped by 569.61% to $683000.0 in 2020, then increased by 24.01% to $847000.0 in 2021, then tumbled by 59.74% to $341000.0 in 2022, then retreated by 2.35% to $333000.0 in 2023.
• The last three Current Deferred Revenue figures came in at $333000.0 (Q2 2023), $340000.0 (Q1 2023), and $341000.0 (Q4 2022), per Business Quant data.